A prototype blood-based screening test evaluated by Cleveland Clinic researchers and others can accurately detect and localize multiple types of cancer, often before symptoms show. The promising results raise hopes that the assay will help achieve the long-sought goal of population-scale early detection of cancer.
PD-L2 plays a significant part in prostate cancer immune modulation and could be a worthwhile prognostic biomarker as well as an immune checkpoint inhibition target, according to a large genetic analysis.
The IsoPSA prostate-specific antigen test could reduce unnecessary prostate biopsies by more than 40% while reliably differentiating among high-grade, low-grade and benign disease, a new validation study has found.
The paradigm for prostate cancer screening with PSA continues to evolve, as do complementary testing tools. Here’s one take from a longtime urologist.
Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services Policy
Results from this first set of patients demonstrate that strong biological signals are present in unscreened cancers that are typically diagnosed at late stages, and that signals correlate highly across assays.
A recent study from Cleveland Clinic shows certain genomic biomarkers appear to be as important as standard clinical factors in identifying which patients are candidates for surveillance or treatment at diagnosis.
Cleveland Clinic Glickman Urological & Kidney Institute physicians will make more than 125 presentations at this year’s AUA meeting. We look forward to seeing you in San Francisco.
A research team led by noted Cleveland Clinic physician-researcher Nima Sharifi, MD, is honing in on what makes certain men more susceptible to prostate cancer that is likely to progress from hormone-sensitive to castration-resistant.
This study shows that adding androgen deprivation therapy to external beam radiation therapy or brachytherapy for early stage prostate cancer can harm ability to reach orgasm, erection quality and ability to function sexually.
Cleveland Clinic researchers cover the gamut when it comes to prostate cancer investigation, from elucidating mechanisms behind resistance to therapy to developing more precise diagnostics.